LUCIUS 卢修斯 利特昔替尼 Ritlecitinib重症斑秃

利特昔替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Ritlecitinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

重症斑秃

Composition:

Each LuciRit capsule contains Ritlecitin

LUCiUS

tosylate 80.15 mg equivalent to

PHARMACEUTICALS

Ritlecitinih
LuciRit is a kinase inhibitor indicated for the
treatment of severe alopecia areata in adult

LuciRit

eodicscems 12 years and older
The ranommse

mended dosage of LuciRit is 50 mg
orally once danly with or without food. If
treatment interruption is indicared, a temporary

Ritlecitinib Capsules

FDA批准

treatment interruption for less than 6 weeks 1s
not expected to result in significant loss of
regrown scalo bair
Capsule should be swallowed whole & no

50mg

Storage: ina dry place and store at 20°C to 25°C.
Warning:
Keep medicine out of the reach of Children. Do
not admiaistered LuciRit in Pregnancy and
Lactation nntiant trontment.

28 Capsules

PLEASESEE PACKAGE INSER
Manufactured and Marketed by

权威认证

Thongmang village. Xaythany district.
Vientiane Capital, Laos
Warning: To be sold by retail on prescrition
ora tegistered physcians only and as directed
lon prescr ption

Rx Only

口碑质量

适应症:
适用于治疗12岁及以上成人和青少年的严重

斑秃。
推荐剂量:
每日口服一次,每次50mg。